Phase II Trial With Subcutaneous Immunotherapy in Patients Sensitized to Phleum Pratense

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2011
Based on EMA (European Medicines Agency) new guidelines on the clinical development of products for immunotherapy for the treatment of allergic diseases the aim of this study is to establish a dose-response relationship for clinical efficacy of Phleum pratense pollen extract subcutaneous vaccine.
Epistemonikos ID: 5f7f6a0849f085fdb4e5359fead298a51447b73d
First added on: May 10, 2024